ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.064,31
-0,17%
S&P 500
5.290,08
-0,13%
US Dollar vs BRL
5,106
-0,47%
Bitcoin
66.545,12
2,00%
Brent Oil
83,715
0,61%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Atea Pharmaceuticals Inc (AVIR)

  7. Atea Pharmaceuticals Inc (AVIR) Notícias

AVIR

Atea Pharmaceuticals (AVIR)

Atea Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVIR
DataHoraFonteTítuloCódigoCompanhia
14/05/202417:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202417:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVIRAtea Pharmaceuticals Inc
14/05/202417:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
07/05/202408:00GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
29/04/202408:00GlobeNewswire Inc.Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
27/03/202408:00GlobeNewswire Inc.Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk PatientsNASDAQ:AVIRAtea Pharmaceuticals Inc
28/02/202418:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
21/02/202409:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024NASDAQ:AVIRAtea Pharmaceuticals Inc
02/02/202423:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
01/02/202418:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/01/202418:05GlobeNewswire Inc.Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19NASDAQ:AVIRAtea Pharmaceuticals Inc
03/01/202409:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
13/11/202309:00GlobeNewswire Inc.Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202318:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
08/11/202309:00GlobeNewswire Inc.Atea Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNASDAQ:AVIRAtea Pharmaceuticals Inc
02/11/202308:00GlobeNewswire Inc.Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
01/11/202308:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call on November 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
06/09/202308:00GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
08/08/202317:05GlobeNewswire Inc.Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/08/202308:00GlobeNewswire Inc.Atea Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
21/06/202317:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AVIRAtea Pharmaceuticals Inc
15/06/202308:00GlobeNewswire Inc.Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir CombinationNASDAQ:AVIRAtea Pharmaceuticals Inc
12/06/202309:20Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
05/06/202317:20GlobeNewswire Inc.Atea Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:AVIRAtea Pharmaceuticals Inc
30/05/202308:00GlobeNewswire Inc.Atea Pharmaceuticals’ Board of Directors Unanimously Rejects Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
23/05/202317:05GlobeNewswire Inc.Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra BiosciencesNASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202317:16Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AVIRAtea Pharmaceuticals Inc
08/05/202317:05GlobeNewswire Inc.Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AVIRAtea Pharmaceuticals Inc
01/05/202317:05GlobeNewswire Inc.Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023NASDAQ:AVIRAtea Pharmaceuticals Inc
28/04/202317:10Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AVIRAtea Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:AVIR

Seu Histórico Recente

BIT
P1BAP7
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados